Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Stereotaxis Inc (STXS)

Stereotaxis Inc (STXS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Results on March 9, 2026 GlobeNewswire - Thu Feb 12, 8:00AM CST

ST. LOUIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will...

STXS : 2.00 (-1.72%)
Klinikum Fürth Establishes Leading Robotic Heart Arrhythmia Program GlobeNewswire - Mon Feb 9, 7:06AM CST

ST. LOUIS, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the launch of...

STXS : 2.00 (-1.72%)
Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter GlobeNewswire - Tue Jan 6, 7:01AM CST

ST. LOUIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained U.S....

STXS : 2.00 (-1.72%)
MarketBeat.com
3 Underrated Robotics Stocks Poised for Huge Gains MarketBeat - Mon Dec 15, 2025

Three potentially underrated robotics stocks—Stereotaxis, Knightscope, and PROCEPT BioRobotics—could be ones to keep an eye on in 2026.

KSCP : 3.52 (-1.12%)
PRCT : 28.12 (-1.33%)
STXS : 2.00 (-1.72%)
Stereotaxis to Participate in Piper Sandler 37th Annual Healthcare Conference GlobeNewswire - Mon Nov 24, 2025

ST. LOUIS, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the company...

STXS : 2.00 (-1.72%)
Stereotaxis Reports 2025 Third Quarter Financial Results GlobeNewswire - Tue Nov 11, 2025

ST. LOUIS, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results...

STXS : 2.00 (-1.72%)
GenesisX Robotic Magnetic Navigation System Receives U.S. FDA Clearance GlobeNewswire - Mon Nov 10, 2025

ST. LOUIS, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it received...

STXS : 2.00 (-1.72%)
Stereotaxis to Report Third Quarter 2025 Financial Results on November 11, 2025 GlobeNewswire - Tue Oct 21, 2025

ST. LOUIS, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will...

STXS : 2.00 (-1.72%)
Stereotaxis Announces EU Launch and 510(k) Submission for Synchrony System to Modernize Interventional Cath Labs GlobeNewswire - Wed Oct 15, 2025

ST. LOUIS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained CE...

STXS : 2.00 (-1.72%)
Lake Street Reaffirms Their Buy Rating on Stereotaxis (STXS) Tipranks - Tue Oct 14, 2025

Lake Street analyst Frank Takkinen reiterated a Buy rating on Stereotaxis today and set a price target of $4.00. The company’s shares closed last Friday at $3.07.Elevate Your Investing Strategy: Take...

STXS : 2.00 (-1.72%)

Barchart Exclusives

Should You Bet on a Short Squeeze in Under Armour Stock? Barchart - 11 minutes ago
Under Armour’s heavy short interest and sharp rebound have stirred volatility. Is another squeeze ahead, or is it over? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot